A provocative new paper introducing the concept of a “placebome” — that is, the complex interplay between genetics and an individual’s response to placebos — raises questions that might ultimately lead to changes in how clinical studies of drugs are evaluated. Kathryn Hall, research fellow in medicine at Beth Israel Deaconess Medical Center, led the study.
